


RSC Advances



This article can be cited before page numbers have been issued, to do this please use: P. Rajakumar and J. Mani, *RSC Adv.*, 2014, DOI: 10.1039/C4RA07992B.



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.


Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This *Accepted Manuscript* will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

Graphical Abstract

Dendrimers containing methyl, ethyl and isopropyl salicylates at the surface were synthesized by divergent approach starting from a simple core unit benzene 1,3,5-tricarboxylic acid.



Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

Synthesis of In-vitro anti-arthritic activity of dendrimers with methyl, ethyl and isopropyl salicylates as surface units

Mani Jayanthi^a and perumal Rajakumar^{*a}

Received (in XXX, XXX) Xth XXXXXXXXX 20XX, Accepted Xth XXXXXXXXX 20XX

DOI: 10.1039/b000000x

Fréchet type dendrimers with salicylates as surface groups have been synthesized by divergent approach and their In-vitro anti-arthritic activities were carried out by inhibition of protein denaturation method.

Introduction

For years, methyl salicylate (Wintergreen Oil) has been found to be the active ingredient of most of the topical analgesics; it is the major ingredient (about 30 %) in Bengay (pain relieving cream, Johnson & Johnson). Methyl salicylate is approved by the U.S. Food and Drug Administration (FDA) and finds many applications¹⁻³ along with the analgesic property such as stimulant or surrogant for sulfur mustard and also finds application in immunohistochemistry³, triboluminescence³; hence the synthesis of dendrimers with methyl and other salicylate analogous were focused. Dendrimers⁴⁻⁵ is one of the most exciting classes of macromolecules that have sparked significant interest in recent years from synthetic, structural and functional points of view. Recently, conjugated dendrimers and bioactive molecules show increased therapeutic efficacy and the delivery of bioactive molecules, is of great importance. Synthesis of dendrimers with anti-bacterial activity has been reported from our group⁶. Synthesis and In-vitro anti-arthritic⁷ as well as anti-inflammatory activities of glycodendrimer bearing α -D-glycopyranosyl surface unit was reported from our laboratory⁸.

In general salicylic acid and its derivatives find a versatile place in pharmaceutical chemistry because of their bioactivity in vitro system. Salicylate derivatives gains the tendency to build up electrical charge when crushed or rubbed with sugar, which can be observed by crushing wintergreen Life Savers candy in a dark room⁹. Further, metal binding properties of salicylate dendrimers has been also reported in 2001¹⁰. Hence it is of great interest to synthesize dendrimers with methyl, ethyl and isopropyl salicylate units at the periphery by means of O-alkylation methodology¹¹⁻¹². Herein, we report the synthesis and in-vitro anti-arthritic activity of Fréchet type dendrimers **1-12** (Figure 1).

In order to study the anti-arthritic activity of salicylate dendrimers **1-12** inhibition of protein denaturation method (using BSA - Bovine Serum Albumin) was employed and diclofenac sodium was used as standard¹³. It was reported that the denaturation of protein is one of the causes for rheumatic arthritic and the production of auto-antigens in certain rheumatoid may be due to in vivo denaturation of proteins¹⁴ and probably involves alteration in electrostatic and hydrophobic interactions, hydrogen and disulfide bonding¹⁵.

Results and discussion

Chemistry

In order to synthesize the required dendrimers with methyl, ethyl and isopropyl salicylate surface units, a multifunctional core unit has to be synthesized. For which, 1,3,5-Tris(bromomethyl)benzene **16** was chosen as core unit and was synthesized from benzene 1,3,5- tricarboxylic acid **13** by esterification in ethanol in the presence of thionyl chloride to give the triester **14** followed by the reduction with LAH (Lithium Aluminium Hydride) in THF¹⁵ to give the corresponding triol **15** and finally brominating the triol **15** with PBr₃ (Scheme 1).

Zero-generation dendrimers (G₀) **1**, **2** and **3** were synthesized by reacting three equivalents of methyl, ethyl and isopropyl salicylate with one equivalent of 1,3,5-tris(bromomethyl)benzene **16** in the presence of potassium carbonate in dry acetone (Scheme 1). In the ¹H NMR spectrum of dendrimer **1**, showed a sharp singlet at δ 3.88, 5.22 for the ester methyl and O-methylene protons respectively in addition to the signals for the aromatic protons. The ¹³C NMR spectrum of dendrimer **1** showed the ester methyl, O-methylene carbon peaks at δ 52.0, 70.6 respectively. The carbonyl carbon appeared at δ 166.8 in addition to the signals for the aromatic carbons. The structure of zero-generation dendrimers **2** and **3** was also confirmed from the spectral and analytical data.

Initially 5-hydroxy isophthalic acid was chosen as building unit in order to synthesize dendrimers with higher generation by convergent approach. In this strategy, deprotection of hydroxyl group of the dendron (which contains the two salicylates groups at 1,3 positions and the hydroxyl group protected as acetyl/ trityl/ TBDMS) either by acidic or basic condition leads to complications as the reaction condition also hydrolyse the ester groups of salicylates. Hence, the O-alkylation method was adapted to synthesize dendrimers **1-12** which eliminates the protection and deprotection protocol in the divergent approach.

In order to synthesize the first-generation (G₁) dendrimer the hexaester **17** was synthesized by reacting three equivalents of diethyl 5-hydroxyisophthalate with one equivalent 1,3,5-tris(bromomethyl)benzene **16** in dry acetone in the presence of potassium carbonate. The alcohol **18** obtained by the LAH reduction of the ethyl hexaester **17** was converted into the






Figure 1 Frechet type salicylate dendrimers




hexabromide **19** using PBr₃ in CHCl₃ (**Scheme 2**). A similar reaction procedure was repeated with the hexabromide **19** to give the dodeca bromide **22** and further the tetracos bromide **25** in 75 % and 73 % yields respectively (**Scheme 2**).

The first-generation (G₁) dendrimers **4**, **5** and **6** were obtained in 71 %, 73% and 69 % respectively by the etherification of six equivalents of methyl, ethyl and isopropyl salicylates with one equivalent of the hexabromide **19** in dry acetone in the presence of potassium carbonate (**Scheme 3**). In the ¹H NMR spectrum, dendrimer **4** showed a sharp singlet at δ 3.89, 5.13 and 5.17 for ester methyl and for two distinct methylene protons respectively. The ¹³C NMR spectrum of dendrimer **4** showed the ester methyl carbon at δ 52.0 and the two distinct methylene carbons at δ 69.8, 70.2 respectively and the carbonyl carbon appeared at δ 166.7. Similarly the structure of dendrimers **5** and **6** were also confirmed from the spectral and analytical data.



Scheme 2

Reagents and conditions: (i) Diethyl 5-hydroxy isophthalate, K_2CO_3 , dry acetone, RT, 24 h (ii) LAH, THF, 50 °C, 8 h (iii) PBr_3 , CH_2Cl_2 , 0 °C-RT, 6 h.



Scheme 3



The second-generation dendrimers (G_2) **7**, **8** and **9** were obtained in 68 %, 69 % and 65 % yields respectively by the etherification of twelve equivalents of methyl, ethyl and isopropyl salicylate with one equivalents of the second-generation dodecabromide **22** in dry acetone in the presence of

potassium carbonate (**Scheme 4**). In the 1H NMR spectrum, compound **7** showed sharp singlet at 3.89, 5.21 and 5.23 for ester methyl and two distinct O-methylene protons respectively in addition to the signals for the aromatic protons. The ^{13}C NMR spectrum of compound **7** showed ester methyl and two distinct

O-methylene carbons at δ 52.0, 70.4 and 70.6 respectively. The carbonyl carbon appeared at δ 165.7 in addition to the signals for other aromatic carbons. The structure of second-generation dendrimers (G_2) **8** and **9** was also confirmed from spectral and analytical data.

The third-generation dendrimers (G_3) **10**, **11** and **12** were obtained in 67 %, 69 % and 64 % yields respectively by the etherification of twenty four equivalents of methyl, ethyl and isopropyl salicylate with one equivalent of the third generation tetracosabromide **25** in dry acetone in the presence of potassium

carbonate (**Scheme 5**). In the ^1H NMR spectrum, compound **10** showed signals at δ 3.85, and 5.09, 5.12 for ester methyl and two distinct O-methylene protons respectively in addition to the signals for the aromatic protons. The ^{13}C NMR spectrum of compound **10** shows ester methyl and two distinct O-methylene carbons at δ 51.8, 70.5 and 70.7 respectively. The carbonyl carbon appeared at δ 163.2 in addition to the signals for the aromatic carbons. The structure of third-generation dendrimers (G_3) **11** and **12** was also confirmed from spectral and analytical data.



Biologicalactivity

Anti-Arthritic Activity

The anti-arthritic activities of all the synthesized dendrimers are concentration dependent and by adapting the standard protocol¹³ the salicylate dendrimers **7-12** were found to possess the maximum anti-arthritic activity (85.4 %, 79.3 %, 70.1 %, 94.3 %, 94.0 % and 92.1 % at 400 µg/mL) when compared to the reference drug diclofenac sodium (58.4 % at 400µg/mL) which




Figure 2 Anti-arthritic activities of salicylate dendrimers **1-12**

reveals that the salicylate dendrimers especially the dendrimer **10** (shows maximum activity even at a concentration of 10 µm/gL) shows better anti-arthritic activity than the reference drug diclofenac sodium. These results also reveal that the salicylate dendrimer are more stable in BSA than the diclofenac sodium.

The degree of anti-arthritic activity of salicylate dendrimers **10**, **12**, **11**, **6**, **7** and **8** at 1000 µg/mL are found to be 99.1 %, 97.9 %, 97.5 %, 92.3 %, 89.1 % and 80.6 % respectively (**Table 1** and **Figure 2**).

Conclusion

In conclusion, methyl, ethyl and isopropyl salicylate dendrimers were synthesized by divergent approach in moderate to good yield. Those dendrimers synthesized were subjected to In-vitro anti-arthritic activity by inhibition of protein denaturation method. The second and third generation dendrimers **7-12** shows superior anti-arthritic activity than the reference drug diclofenac sodium at a concentration 100 µg/mL and above. Especially the third-generation (G3) dendrimer **10** shows better activity even at low concentration.

Experimental section

Chemistry

General: All chemicals and solvents were purchased commercially and used as such without further purification. All melting points of those synthesized compounds are uncorrected and the ¹H NMR and ¹³C NMR spectra were recorded on Bruker 300-MHz instrument in CDCl₃ and DMSO-d₆ solvent with tetramethylsilane (TMS) as an internal reference. Elemental analyses were carried out on a Perkin-Elmer CHNS 2400 instrument. Column chromatography was performed on silica gel (ACME, 100–200 mesh). Routine monitoring of the reaction was made using thin-layer chromatography (TLC) developed on 0.25 mm glass plates coated with silica gel-G (ACME) and visualized with iodine.

Table 1 In vitro anti-arthritic activity of salicylate dendrimers **1–12** by inhibition of protein denaturation method (Bovine Serum Albumin)

Dendrimer	Activity (% Inhibition of protein denaturation)						
	10 µg/ml	50 µg/ml	100 µg/ml	200 µg/ml	400 µg/ml	800 µg/ml	1000 µg/ml
1	3.66±0.86	3.97±1.02	7.07±0.56	13.61±0.42	22.21±1.08	31.93±0.98	45.52±0.64
2	2.98±0.99	2.97±0.84	3.14±1.06	11.51±1.04	19.87±2.00	25.90±1.93	31.03±0.54
3	2.72±1.58	2.84±1.92	2.92±0.72	11.13±0.94	18.84±0.53	26.68±0.82	30.86±1.54
4	7.07±1.32	9.81±0.45	15.79±0.94	25.90±0.91	46.01±0.74	55.24±0.97	64.10±1.05
5	3.97±0.97	6.18±0.63	13.09±0.62	21.11±0.84	37.13±0.93	48.81±1.31	56.62±0.79
6	3.33±0.86	6.03±1.38	12.84±0.55	19.97±0.91	35.23±0.94	42.61±2.01	49.62±0.91
7	12.72±0.82	16.33±0.80	48.78±0.56	57.74±1.03	85.44±0.76	86.62±0.93	92.31±0.54
8	11.09±1.23	15.83±0.92	42.16±0.67	54.80±0.59	79.26±0.62	83.21±0.81	89.08±0.29
9	10.75±0.95	13.32±0.81	41.34±0.78	48.05±0.62	70.08±0.93	72.34±0.75	80.64±0.34
10	70.92±0.91	80.64±0.54	91.09±0.19	92.38±0.68	94.29±1.08	96.64±1.04	99.11±0.97
11	27.93±0.94	52.12±0.42	73.98±0.45	88.14±0.84	93.98±0.82	94.28±1.13	97.52±1.54
12	27.71±1.01	40.13±0.47	71.65±0.95	87.50±0.78	92.11±0.87	95.08±0.91	97.91±0.53
Diclofenac Sodium	9.50±1.21	16.32±0.64	22.20±0.95	39.37±0.64	58.42±0.87	64.49±1.08	81.42±0.98

General procedure for esterification

To a solution of the carboxylic acid (5 g) in ethanol (50 ml), SOCl₂ (about 1 ml) was added at 0 °C. The reaction mixture was then refluxed for 12 h. The solvent was removed under reduced pressure. The residue, thus obtained was dissolved in CHCl₃ (200 ml), washed with water (2x 100 ml), brine (100 ml) and dried over anhydrous Na₂SO₄. Removal of the solvent afforded the esters ^{17a-e} which was used as such without further purification.

General procedure for LAH reduction

To a stirred suspension of LAH (1.2 eq./ester group) in dry THF, the ester compound in THF was added slowly under N₂ atmosphere at 0-5 °C. The above reaction mixture was then allowed to reach room temperature and heated at 50 °C for 8 h. It was then cautiously quenched with 10% NaOH solution at 0 °C. The reaction mixture was then filtered, and the residue obtained was agitated with THF (3x50ml) and the combined THF layers were evaporated. The residue obtained was dissolved in CHCl₃ and extracted with CHCl₃ (3x100ml), washed with brine (100 ml), dried over Na₂SO₄ and evaporated to give the hydroxyl compound as crude product, which was purified using silica gel 100-200 using CHCl₃:hexane (3:5) as eluent.

1,3,5-tris(Hydroxy methyl) benzene (15)

White solid. mp: 123-125 °C; Yield: 73 %; ¹H NMR (300 MHz, DMSO-*d*₆): δ_H 4.47-4.49 (d, *J*=5.7 Hz, 6H), 5.18-5.22 (m, 3H), 7.13 (s, 3H); ¹³C NMR (75 MHz, DMSO-*d*₆): δ_C 62.9, 122.9, 142.0

(5,5',5''-(benzene-1,3,5-triyltris(methylene)) tris(oxy)tris(benzene-5,3,1-triyl))hexamethanol (18)

Off-white solid. mp: 138-142 °C; Yield: 71 %; ¹H NMR (300 MHz, DMSO-*d*₆): δ_H 3.38 (s, 12H), 4.39-4.49 (m, 6H), 6.37-6.38 (m, 9H), 6.56-6.60 (m, 3H); ¹³C NMR (75 MHz, DMSO-*d*₆): δ_C 61.9, 68.9, 114.5, 122.2, 125.8, 137.3, 138.7, 153.7; Anal. calcd for C₃₃H₃₆O₉: C, 68.74; H, 6.29; found: C, 68.72; H, 6.18.

General procedure for bromination

To a solution of triol / hexa / dodeca / tetracosahydroxy compound (9.4 mmol) in CHCl₃ (50 ml) was added an excess of PBr₃ at 0 °C and stirred for 1 h. The reaction mixture was then allowed to reach room temperature and stirred for further 6 h. After the completion of the reaction, it was extracted with CHCl₃ (3x100 ml), washed with aq., NaHCO₃ (100 ml), brine (100 ml), dried over Na₂SO₄ and evaporated. The residue obtained was purified by column chromatography using CHCl₃/hexane (2:3) as eluent.

1,3,5-tris(Bromomethyl)benzene (16)

White solid. mp: 79-81 °C; Yield: 88 %; ¹H NMR (300 MHz, CDCl₃): δ_H 4.46 (s, 6H), 7.36 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): δ_C 32.2, 129.6, 139.1; Anal. calcd for C₉H₉Br₃: C, 30.27; H, 2.54; found: C, 30.21; H, 2.48; m/z: 357 [M+1]

1,3,5-tris((3,5-bis(Bromomethyl)phenoxy)methyl)benzene (19)

White solid. mp: 135-138 °C; Yield: 85 %; ¹H NMR (300 MHz, CDCl₃): δ_H 4.43 (s, 12H), 5.11 (s, 6H), 6.96 (s, 6H), 7.03 (s, 3H), 7.48 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): δ_C 69.5, 69.7, 115.4, 122.2, 126.1, 137.4, 139.7, 158.9; Anal. calcd for C₃₃H₃₀Br₆O₃: C, 41.55; H, 3.17; found: C, 40.98; H, 3.10.

1,3,5-Tris((3,5-bis((3,5-bis(bromomethyl)phenoxy)methyl)phenoxy)methyl) benzene (22)

Off-white solid. mp: 148-152 °C; Yield: 85 %; ¹H NMR (300 MHz, CDCl₃): δ_H 5.04 (s, 30H), 5.09 (s, 12H), 6.87-6.90 (m, 12H), 7.10-7.13 (m, 3H), 7.40-7.47 (m, 6H), 7.86 (s, 3H), 7.87-7.88 (m, 6H); ¹³C NMR (75 MHz, CDCl₃): δ_C 58.4, 58.5, 115.6, 121.3, 124.2, 139.6, 139.7, 156.9.

1,3,5-Tris((3,5-bis((3,5-bis(bromomethyl)phenoxy)methyl)phenoxy)methyl)phenoxy)methyl)benzene (25)

Off-white solid. mp: 172-174 °C; Yield: 83 %; ¹H NMR (300 MHz, CDCl₃): δ_H 5.02 (s, 48H), 5.03 (s, 42H), 6.79 (s, 24H), 6.87-6.90 (m, 12H), 7.02-7.13 (m, 12H), 7.40-7.46 (m, 12H), 7.80-7.86 (m, 6H); ¹³C NMR (75 MHz, CDCl₃): δ_C 69.4, 69.7, 115.4, 115.5, 121.8, 126.1, 136.4, 137.4, 157.4

General Procedure for etherification

A solution containing the diethyl 5-hydroxy isophthalate / salicylates (2.1 mmol/4.2 mmol/8.4 mmol/16.8 mmol) and the tribromide **16**/ hexabromide **19**/ dodecabromide **22**/ tetracosabromide **25** (0.7 mmol) was stirred with K₂CO₃ (5.1 mmol/10.1 mmol/15.1 mmol/ 20.1 mmol) in dry acetone at room temperature for 24 h after which the reaction mixture was filtered-off and the solvent was evaporated to dryness to give the multifunctional ester compound / dendrimer as residue which was then purified by column chromatography using hexane: CHCl₃ (3:2) as eluent.

Hexaethyl5,5',5''-(benzene-1,3,5-triyltris(methylene))tris(oxy)triisophthalate (17)

White solid. mp: 122-124 °C; Yield: 83 %; ¹H NMR (300 MHz, CDCl₃): δ_H 1.39-1.44 (m, 18H), 4.37-4.44 (m, 12H), 5.21 (s, 6H), 7.57 (s, 3H), 7.85 (d, *J*=0.9 Hz, 6H), 8.31 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): δ_C 14.4, 61.5, 70.1, 119.9, 123.4, 126.4, 132.2, 137.4, 158.6, 165.7

Dodecaethyl 5,5',5'',5'''-(5,5',5''-(benzene-1,3,5-triyltris(methylene)) tris(oxy)tris(benzene-5,3,1-triyl))hexakis(methylene) hexakis(oxy)hexaisophthalate (20)

Off-white solid. mp: 174-177 °C; Yield: 84 %; ¹H NMR (300 MHz, CDCl₃): δ_H 1.36-1.43 (m, 36H), 4.34-4.43 (m, 24H), 5.09 (s, 12H), 5.12 (s, 6H), 6.95 (s, 6H), 7.07 (s, 3H), 7.14 (s, 3H), 7.81 (s, 12H), 8.21-8.28 (m, 6H); ¹³C NMR (75 MHz, CDCl₃): δ_C 16.5, 59.3, 69.5, 69.7, 115.0, 115.4, 115.5, 112.2, 126.1, 137.4, 139.7, 158.9; Anal. calcd for C₁₀₅H₁₀₈O₃₃: C, 66.45; H, 5.74; found: C, 66.30; H, 5.63.

Compound 23

Off-white solid. mp: 185-187 °C; Yield: 81 %; ¹H NMR (300 MHz, CDCl₃): δ_H 1.38-1.41 (m, 72H), 4.36-4.43 (m, 48H), 5.08 (s, 24H), 5.12 (s, 18H), 6.99 (s, 6H), 7.09 (s, 12H), 7.12 (s, 6H), 7.75 (s, 6H), 7.81 (s, 24H), 8.28 (s, 12H); ¹³C NMR (75 MHz, CDCl₃): δ_C 14.3, 61.5, 69.9, 70.1, 114.4, 120.0, 120.9, 122.1, 123.2, 132.1, 138.3, 158.7, 165.9.

Dendrimer 1

Off-white solid. mp: 75-77 °C; Yield: 74 %; ¹H NMR (300 MHz, CDCl₃): δ_H 3.88 (s, 9H), 5.22 (s, 6H), 6.98-7.02 (m, 6H), 7.39-7.47 (m, 3H), 7.59 (s, 3H), 7.81-7.85 (m, 3H); ¹³C NMR (75 MHz, CDCl₃): δ_C 52.0, 70.6, 114.1, 120.8, 124.8, 125.9, 131.8, 133.5, 137.7, 158.0, 166.8; Anal. calcd for C₃₃H₃₀O₉: C, 69.45; H, 5.30; found: C, 69.23; H, 5.22; m/z: 571 [M+1]

Dendrimer 2

Off-white solid. mp: 81-83 °C; Yield: 75 % ; ¹H NMR (300 MHz, CDCl₃): δ_H 1.26-1.31 (m, 9H), 4.30-4.37 (m, 6H), 5.19 (s, 6H), 6.97-7.02 (m, 6H), 7.38-7.43 (m, 3H), 7.58 (s, 3H), 7.79-7.82 (m, 3H); ¹³C NMR (75 MHz, CDCl₃): δ_C 14.3, 60.9, 70.6, 114.0, 120.7, 121.3, 125.1, 131.7, 133.3, 137.6, 157.9, 166.4; Anal. calcd for C₃₆H₃₆O₉: C, 70.57; H, 5.92; found: C, 70.13; H, 5.67; m/z: 613 [M+1]

Dendrimer 3

Off-white solid. mp: 67-69 °C; Yield : 73 % ; ¹H NMR (300 MHz, CDCl₃): δ_H 1.27-1.29 (d, J= 6.0 Hz, 18H), 5.19 (s, 6H), 5.21-5.27 (m, 6H), 6.97-7.02 (m, 6H), 7.37-7.42 (m, 3H), 7.58 (s, 3H), 7.76-7.79 (m, 3H); ¹³C NMR (75 MHz, CDCl₃): δ_C 21.9, 68.2, 70.6, 113.9, 120.7, 121.9, 125.4, 131.4, 133.0, 137.6, 157.8, 166.0; Anal. calcd for C₃₉H₄₂O₉: C, 71.54; H, 6.47; found: C, 71.46; H, 6.42.

Dendrimer 4

Off-white solid. mp: 110-112 °C; Yield : 71 % ; ¹H NMR (300 MHz, CDCl₃): δ_H 3.87 (s, 18H), 5.13 (12 H, s), 5.17 (s, 6H), 6.96 (br, 6H), 6.99 (br, 6H), 7.14 (s, 6H), 7.18 (s, 3H), 7.38-7.43 (m, 6H), 7.48 (s, 3H), 7.80-7.82 (m, 6H); ¹³C NMR (75 MHz, CDCl₃): δ_C 51.4, 69.5, 69.7, 111.8, 113.9, 115.4, 122.2, 126.1, 137.4, 139.7, 147.8, 158.9, 167.4; Anal. calcd for C₈₁H₇₂O₂₁: C, 70.42; H, 5.25; found: C, 70.36; H, 5.18; m/z: 1382 [M+1]

Dendrimer 5

Off-white solid; Yield : 73 % ; ¹H NMR (300 MHz, CDCl₃): δ_H 1.24-1.33 (m, 18H), 4.32-4.36 (m, 12H), 5.10 (s, 12H), 5.14 (s, 6H), 6.95 (s, 6H), 6.98 (s, 6H), 7.11 (s, 3H), 7.16 (s, 6H), 7.39 (s, 6H), 7.48 (s, 3H), 7.78-7.81 (d, J= 7.5 Hz, 6H); ¹³C NMR (75 MHz, CDCl₃): δ_C 14.3, 60.9, 70.2, 70.4, 112.8, 113.8, 113.9, 120.7, 120.8, 121.3, 131.6, 131.7, 133.3, 138.3, 157.7, 166.4; Anal. calcd for C₈₇H₈₄O₂₁: C, 71.30; H, 5.78; found: C, 70.89; H, 5.42.

Dendrimer 6

Off-white solid; Yield : 69 % ; ¹H NMR (300 MHz, CDCl₃): δ_H 1.24-1.33 (m, 36H), 4.32-4.44 (m, 6H), 5.09 (s, 12H), 5.14 (s, 6H), 5.21-5.27 (m, 6H), 6.95-6.98 (m, 6H), 7.11 (s, 6H), 7.16 (s, 3H), 7.39 (s, 6H), 7.48 (s, 3H), 7.79-7.81 (m, 6H); ¹³C NMR (75 MHz, CDCl₃): δ_C 21.9, 68.2, 69.8, 70.6, 113.3, 120.1, 122.2, 125.4, 131.4, 133.8, 136.9, 158.8, 166.6; Anal. calcd for C₉₃H₉₆O₂₁: C, 72.08; H, 6.24; found: C, 71.84; H, 6.12.

Dendrimer 7

Pale Brown Gum; Yield: 68 % ; ¹H NMR (300 MHz, CDCl₃): δ_H 3.89 (s, 36H), 5.21 (s, 24), 5.23 (s, 18H), 6.96 (s, 6H), 6.99-7.01 (m, 24H), 7.36-7.39 (m, 12H), 7.42-7.43 (m, 12H), 7.57-7.76 (m, 12H), 7.78-7.79 (m, 12H); ¹³C NMR (75 MHz, CDCl₃): δ_C 52.0, 70.4, 70.6, 109.4, 114.1, 120.8, 124.8, 125.9, 131.8, 133.5, 137.7, 142.1, 158.0, 165.7; Anal. calcd for C₁₇₇H₁₅₆O₄₅: C, 70.79; H, 5.24; found: C, 70.64; H, 5.13.

Dendrimer 8

Pale Brown Gum; Yield: 69 %; ¹H NMR (300 MHz, CDCl₃): δ_H 1.21-1.32 (m, 36H), 4.31-4.39 (m, 24H), 6.98 (s, 24H), 7.02 (s, 18H), 7.04-7.11 (m, 12H), 7.14 (s, 6H), 7.20-7.31 (m, 24H), 7.78-7.88 (m, 12H), 8.12-8.17 (m, 24H); Anal. calcd for C₁₈₉H₁₈₀O₄₅: C, 71.58; H, 5.72; found: C, 71.34; H, 5.48.

Dendrimer 9

Brown Gum; Yield: 64 % ; ¹H NMR (300 MHz, CDCl₃): δ_H 1.23-1.29 (m, 72H), 5.12 (s, 24H), 5.16 (s, 18H), 5.48-5.52 (m, 12H),

6.87-6.89 (m, 6H), 6.93-7.09 (m, 12H), 7.13-7.28 (m, 24H), 7.68-7.85 (m, 12H), 7.98-8.13 (m, 24H); Anal. calcd for C₂₀₁H₂₀₄O₄₅: C, 72.29; H, 6.16; found: C, 72.12; H, 6.02.

Dendrimer 10

Brown Gum; Yield: 67 %; ¹H NMR (300 MHz, CDCl₃): δ_H 3.85 (s, 72H), 5.09 (s, 48H), 5.12 (s, 42H), 6.95 (s, 36H), 7.07 (s, 6H), 7.74 (s, 24H), 7.81 (s, 24H), 8.12-8.21 (m, 48H), 8.28 (s, 24H); ¹³C NMR (75 MHz, CDCl₃): δ_C 51.8, 70.5, 70.7, 116.4, 117.5, 117.7, 118.9, 121.7, 126.4, 131.3, 132.9, 133.7, 133.9, 137.0, 148.5, 161.7, 163.2; Anal. calcd for C₃₉₃H₃₇₂O₉₃: C, 71.70; H, 5.70; found: C, 71.30; H, 5.56.

Dendrimer 11

Brown Gum; Yield: 69 %; ¹H NMR (300 MHz, CDCl₃): δ_H 1.21-1.26 (m, 72H), 4.34-4.45 (m, 24H), 5.04 (s, 48H), 5.09 (s, 42H), 6.88 (s, 48H), 6.96-6.99 (m, 36H), 7.10-7.13 (m, 24H), 7.39-7.48 (m, 24H), 7.79 (s, 8H), 7.84-7.87 (m, 22H); Anal. calcd for C₃₉₃H₃₇₂O₉₃: C, 71.70; H, 5.70; found: C, 71.30; H, 5.56.

Dendrimer 12

Dark Brown Gum; Yield: 64 % ; ¹H NMR (300 MHz, CDCl₃): δ_H 1.34-1.36 (m, 144H), 5.21 (s, 48 H), 5.22 (s, 42H), 5.66-5.78 (m, 24H), 6.64-6.66 (m, 23H), 7.01 (s, 34H), 7.09-7.12 (m, 32H), 7.26-7.38 (m, 22H), 7.54 (s, 31H), 7.85-7.88 (m, 12H), 7.94-7.97 (m, 8H); ¹³C NMR (75 MHz, CDCl₃): δ_C 21.8, 67.6, 68.9, 116.2, 116.7, 117.5, 117.6, 118.9, 120.7, 126.1, 131.3, 133.0, 133.7, 133.8, 137.0, 150.4, 161.7, 163.2; Anal. calcd for C₄₁₇H₄₂₀O₉₃: C, 72.38; H, 6.12; found: C, 72.30; H, 6.03.

Anti-Arthritic Studies

Test solutions consist of 0.45 ml of bovine serum albumin (5% w/v aqueous) and 0.05 ml of dendrimers **1-12** in various concentrations were prepared and the pH was adjusted to 6.3 by adding a small amount of 1 N HCl. In a similar manner test control and standard solutions were prepared by adding 0.05 ml of distilled water and 0.05 ml diclofenac sodium respectively to 0.45 ml of bovine serum albumin. Product control was prepared by adding 0.05 ml of test solutions in various concentrations to 0.45 ml of distilled water. The samples prepared were incubated at 37 °C for 20 minutes and then heated to 57 °C for 3 minutes. After cooling, 2.5 ml of phosphate buffer (pH 6.3) was added to each solution. The optical densities (OD) of the samples were measured from a spectrophotometer at 660 nm. Each experiment was done in triplicate and taken the average.

The percentage inhibition of Protein denaturation was calculated as follows.

$$\text{Percent Inhibition} = \frac{100 - [\text{OD of test solution} - \text{OD of product control}]}{\text{OD of test control}} \times 100$$

The control represents 100 % protein denaturation and the result was compared with diclofenac sodium treated samples.

Acknowledgements

The authors thank DST-PURSE, New Delhi for financial assistance, DST-FIST for providing NMR facility to the department and Faculty of Pharmacy, Sri Ramachandra University, Chennai-600 116 for in-vitro anti-arthritic studies.

References and notes

^a Address: Department of Organic Chemistry, University of Madras, Chennai-600025. Telephone: 044-22202810; E-mail: perumalrajakumar@gmail.com

[†] Electronic Supplementary Information (ESI) available: The ¹H and ¹³C spectra of all the synthesized compounds and dendrimers. See DOI: 10.1039/b000000x/

- James, D.G.; Price, T.S., *J. Chem. Ecol.* **2004**, 30 (8), 1613-28.
- Harvey, E.N., *Science*. **1939**, 90 (2324), 35-36.
- Bartlett-Hunt, S.L.; Knappe, R.U. Detlef et al., *Critical Reviews in Environmental Science and Technology*. **2008**, 38 (2), 112-136.
- Hawker, C. J.; Frechet, J. M. J. *New Methods of Polymer Synthesis*, Vol. 2; Ebdon, J.R.; Eastmond G.C., (Eds). *New methods of polymer synthesis*. Chap. 2. Blackie Academic and Professional: Glasgow, UK (**1995**).
- Frechet, J.M.J.; Tomalia, D.A., *Dendrimers and Other Dendritic Polymers*. John Wiley & Sons, Ltd.: Chichester (**2001**).
- Rajakumar, P.; Ganesan, K.; Jayavelu, S.; Murugesan, K., *Synthesis* **2006**, 3, 528-532.
- Rajakumar, P.; Anandhan, R.; Kannan, A., *Supramolecular Chemistry* **2013**, 25 (6), 362-370.
- Rajakumar, P.; Anandhan, R., *European Journal of Medicinal Chemistry* **2011**, 46, 4687-4695.
- Altman, J.S.; Tyrer, N.M.; Strausfeld, N.J.; Miller, T.A., *Neuroanatomical Techniques*, Springer-Verlag (**1980**) 373-402.
- Cohen, S.M.; Petoud, S.; Raymond, K.N, *Chem. Eur. J.* **2001**, 7, 272-279.
- Hawker, C.J.; Frechet, J.M.J, *J. Chem. Soc., Chem. Commun.* **1990**, 1010-1013
- Hawker, C.J.; Frechet, J.M.J, *J. Am. Chem. Soc.* **1990**, 112, 7638-7647.

- Mizushima, Y. *Lancet* **1966**, 2, 443.
- Brown, J.H.; Mackey, H.K. *Proc. Soc. Exp. Biol. Med.* **1968**, 128, 225.
- Grant, N.H.; Alburn, H.E.; Kryzanasuskas, C. *Biochem. Pharmacol.* **1970**, 19, 715.
- Freeman, A.W.; Chrisstoffels, L.A.J.; Frechet, J.M.J, *J. Org. Chem.* **2000**, 65, 7612-7617.
- (a) *Methyl Salicylate*: Yield: 93 %; ¹H NMR (300 MHz, CDCl₃): δ_H 3.95 (s, 3H), 6.86-6.91 (dt, *J*₁=5.2 Hz, *J*₂=1.2 Hz, 1H), 6.97-7.0 (dd, *J*₁=7.2 Hz, *J*₂=1.2 Hz, 1H), 7.43-7.49 (dt, *J*₁=5.2 Hz, *J*₂=1.2 Hz, 1H), 7.82-7.86 (dd, *J*₁=4.8 Hz, *J*₂=1.8 Hz, 1H), 10.77 (s, 1H); ¹³C NMR (75 MHz, CDCl₃): δ_C 52.3, 112.4, 117.6, 119.2, 129.9, 135.7, 161.6, 170.6 ;
(b) *Ethyl Salicylate*: Yield: 95 %; ¹H NMR (300 MHz, CDCl₃): δ_H 1.30-1.34 (t, *J*= 7.2 Hz, 3H), 4.27-4.35 (q, *J*= 7.2 Hz, *J*₂=14.4 Hz, 2H), 6.75-6.81 (m, 1H), 6.87-6.90 (dd, *J*₁=0.9 Hz, *J*₂=8.4 Hz, 1H), 7.32-7.38 (m, 1H), 7.74-7.77 (dd, *J*₁=3.6 Hz, *J*₂=8.1 Hz, 1H), 10.78 (s, 1H); ¹³C NMR (75 MHz, CDCl₃): δ_C 13.4, 61.7, 111.6, 115.4, 117.9, 128.8, 134.2, 160.9, 170.4;
(c) *Isopropyl Salicylate*: Yield: 93 %; ¹H NMR (300 MHz, CDCl₃): δ_H 1.34-1.36 (d, *J*=6.0 Hz, 6H), 5.19-5.26 (m, 1H), 6.61-6.66 (m, 2H), 7.22-7.28 (m, 1H), 7.85-7.88 (m, 1H), 10.50 (s, 1H); ¹³C NMR (75 MHz, CDCl₃): δ_C 22.0, 67.6, 111.6, 116.2, 116.6, 131.3, 133.49, 150.4, 167.7;
(d) *Diethyl 5-hydroxy isophthalate*: Yield: 92 %; ¹H NMR (300 MHz, CDCl₃): δ_H 1.39-1.44 (t, *J*=7.2 Hz, 6H), 4.37-4.45 (q, *J*₁=7.2 Hz, *J*₂=14.4 Hz, 4H), 7.15 (s, 1H), 7.81 (d, *J*=1.5 Hz, 2H), 8.24 (1H, s); ¹³C NMR (75 MHz, CDCl₃): δ_C 14.2, 61.7, 121.0, 122.6, 132.0, 156.5, 166.2; MS: *m/z* 239 (M⁺);
(e) *Triethyl benzene-1,3,5-tricarboxylate(14)*: Yield: 93 %; ¹H NMR (300 MHz, CDCl₃): δ_H 1.42-1.47 (t, *J*=7.2 Hz, 9H), 4.42-4.49 (q, *J*₁=7.2 Hz, *J*₂=14.4 Hz, 6H), 8.85 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): δ_C 14.3, 61.7, 131.4, 134.4, 165.1